Boryung-Astellas co-promote ‘Harnal D’ & ‘Vesicare’

Published: 2016-11-14 10:12:07

Updated: 2016-11-14 10:12:07

Boryung Pharm and Astellas Pharma Korea will start the co-promotion business for the dysuria symptom enhancer “Harnal D’ and the overactive bladder symptom therapy ‘Vesicare.’

Boryung Pharm(CEO Tae-Hong Choi) and Astellas Pharma Korea(President Hae-Do Jung) signed a co-promotion agreement of ‘Harnal D’ and ‘Vesicare’ at Hotel Shilla on November 9.

Under the co-promotion agreement, Boryung Pha...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.